Get Magazines for free

Categories

10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Please note

Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”

Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments
.

Archives : Old artciles

Monday, March 30, 2009

Torrent Pharma: Bouncing back to good health

Scripscan:Torrent Pharmaceuticals Ltd
cmp:128
Traded in:Nse-bse

Story:Given its performance and growth potential, Torrent Pharma is a relatively under-valued stock in the Indian pharma space. However, the stock has
out-performed the broader indices in the past 12 months. While the Sensex declined by over 40% last year, the stock is trading around the same level.company has been on a growth path in the past two fiscals. While the losses registered by the German subsidiary adversely impacted its overall growth in FY08, the company is showing signs of a recovery and is likely to bounce back by FY10.

Business:Incorporated in 1972, the Ahmedabad-based Torrent Pharma is engaged in the production of drug formulations and contract manufacturing. The domestic branded formulations, exports and contract manufacturing contribute 44%, 45% and 11% to the company’s total revenues respectively.The company has a strong presence in the high-value chronic therapies of cardio vascular, gastrointestinal, central nervous system (CNS) and anti-diabetes . The company’s top 10 brands constituted 41% of its total domestic formulation sales in FY’ 08 as against 44% in the previous year.Torrent major international operations are situated in Brazil, Europe, Russia and the former Soviet republics in Eastern Europe and Central Asia. It has nine wholly owned subsidiaries in various regulated and semi-regulated markets abroad. The pharma company’s other revenue source is contract manufacturing, which largely comprises of sourcing, manufacturing and supplying insulin formulations under a third-party brand name.Torrent is steadily ramping up its product development activity. Research and development (R&D ) expenditure account for 7% of its revenues, with a 70:30 spend ratio towards product development and discovery research. The company has a healthy product pipeline for the US and European markets on expiry of the patents. It also undertakes new drug discovery research and currently has seven new chemical entities (NCE) in diabetes and related ailments.

Growth Strategy:The domestic formulations business and operations in the semi-regulated markets of Brazil, Russia and countries in Eastern Europe and Central Asia are the growth drivers for the company. These markets are witnessing a double-digit volume growth. The company is bullish on its international generic business. Many of its international operations have achieved critical size, leading to revenue traction.Torrent’s domestic business also benefits from the tax-free status enjoyed by its manufacturing operations. Its units, located at Baddi and Sikkim,
enjoy tax exemption for 5 and 10 years respectively. This enables it to compete effectively in a pricesensitive market.

Financials:The company’s net sales rose at a compound annual growth rate (CAGR) of 28.7% over the past five years to Rs 1355 crore in FY08. The net profits have grown at a CAGR of 25% to Rs 134.6 crore in FY08. At an average dividend payout of 25% over the past three years, the company’s dividend payouts have grown at a CAGR of 12% over the past five years, half than the corresponding profit growth. The company has positive operating cash flows and a debt equity ratio lower than one.The company’s sales growth in FY08 was weighed down by de-growth in its German subsidiary Heumann in wake of severe price erosions and a volume shift to unexplored segments. The company expects to shift 70-80 % of Heumann’s manufacturing to India. The subsidiary is thereby expected to break even in FY10.The past twelve months have reflected the recovery in the company’s operations and profitability . The position is likely to improve going forward. Recent measures such as realignment of field operations, cost-cutting , and shifting of manufacturing from Germany to India are expected to beef up the profit margins.

Valuations:Torrent has outperformed the Sensex and is currently valued at little over its annual turnover. It witnessed a stable 22% return on capital employed (ROCE) over the past two years. It is an under-valued stock among similar-sized peers and holds promise for investors looking for value in the mid-cap space.

Source:ET

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
 
x

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner